Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance
Marco Rusnati,
Davide Sala,
Alessandro Orro,
Antonella Bugatti,
Gabriele Trombetti,
Elena Cichero,
Chiara Urbinati,
Margherita Di Somma,
Enrico Millo,
Luis J. V. Galietta,
Luciano Milanesi,
Paola Fossa,
Pasqualina D’Ursi
Affiliations
Marco Rusnati
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
Davide Sala
Institute for Biomedical Technologies, National Research Council (ITB-CNR), 20090 Segrate, Italy
Alessandro Orro
Institute for Biomedical Technologies, National Research Council (ITB-CNR), 20090 Segrate, Italy
Antonella Bugatti
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
Gabriele Trombetti
Institute for Biomedical Technologies, National Research Council (ITB-CNR), 20090 Segrate, Italy
Elena Cichero
Department of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, 16132 Genoa, Italy
Chiara Urbinati
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
Margherita Di Somma
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
Enrico Millo
Department of Experimental Medicine, Section of Biochemistry, University of Genoa, 16132 Genoa, Italy
Luis J. V. Galietta
Istituto Giannina Gaslini, 16147 Genoa, Italy
Luciano Milanesi
Institute for Biomedical Technologies, National Research Council (ITB-CNR), 20090 Segrate, Italy
Paola Fossa
Department of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, 16132 Genoa, Italy
Pasqualina D’Ursi
Institute for Biomedical Technologies, National Research Council (ITB-CNR), 20090 Segrate, Italy
Cystic fibrosis (CF) is mainly caused by the deletion of Phe 508 (ΔF508) in the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. New drugs able to rescue ΔF508-CFTR trafficking are eagerly awaited. An integrated bioinformatics and surface plasmon resonance (SPR) approach was here applied to investigate the rescue mechanism(s) of a series of CFTR-ligands including VX809, VX770 and some aminoarylthiazole derivatives (AAT). Computational studies tentatively identified a large binding pocket in the ΔF508-CFTR nucleotide binding domain-1 (NBD1) and predicted all the tested compounds to bind to three sub-regions of this main pocket. Noticeably, the known CFTR chaperone keratin-8 (K8) seems to interact with some residues located in one of these sub-pockets, potentially interfering with the binding of some ligands. SPR results corroborated all these computational findings. Moreover, for all the considered ligands, a statistically significant correlation was determined between their binding capability to ΔF508-NBD1 measured by SPR and the pockets availability measured by computational studies. Taken together, these results demonstrate a strong agreement between the in silico prediction and the SPR-generated binding data, suggesting a path to speed up the identification of new drugs for the treatment of cystic fibrosis.